Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-07291177 in Healthy Adults
NCT05434091Phase 1Withdrawn
- Sponsor
- Pfizer
- Start
- Aug 2022
- Primary completion
- Mar 2023
01
Overview
Phase 1, randomised, double-blind trial of PF-07291177 (3 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Treatment-Related Adverse Events, Number of Participants With Clinical Laboratory Abnormalities and 3 more. Planned start Aug 2022; status: withdrawn.
02
Drugs
PF-07291177
Beyond the preview
Go deeper on NCT05434091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05434091.